Patents by Inventor John J. Acton

John J. Acton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
    Patent number: 6852738
    Abstract: A class of acyl sulfamides comprises compounds that are potent ligands for PPAR gamma and generally have antagonist or partial agonist activity. The compounds may be useful in the treatment, control or prevention of obesity, non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, inflammation, and other PPAR gamma mediated diseases, disorders and conditions.
    Type: Grant
    Filed: January 25, 2002
    Date of Patent: February 8, 2005
    Assignee: Merck & Co., Inc.
    Inventors: A. Brian Jones, John J. Acton, III
  • Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
    Publication number: 20040073037
    Abstract: A class of acyl sulfamides comprises compounds that are potent ligands for PPAR gamma and generally have antagonist or partial agonist activity. The compounds may be useful in the treatment, control or prevention of obesity, non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, inflammation, and other PPAR gamma mediated diseases, disorders and conditions.
    Type: Application
    Filed: July 29, 2003
    Publication date: April 15, 2004
    Inventors: A. Brian Jones, John J. Acton III
  • N-substituted indoles useful in the treatment of diabetes
    Patent number: 6525083
    Abstract: Certain N-substituted indoles having aryloxyacetic acid, substituents are agonists or partial agonists of PPAR gamma, and are useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR mediated diseases, disorders and conditions.
    Type: Grant
    Filed: July 25, 2001
    Date of Patent: February 25, 2003
    Assignee: Merck & Co., Inc.
    Inventors: John J. Acton, III, Regina Marie Black, Anthony Brian Jones, Harold Blair Wood
  • N-substituted indoles useful in the treatment of diabetes
    Publication number: 20020042441
    Abstract: Certain N-substituted indoles having aryloxyacetic acid substituents are agonists or partial agonists of PPAR gamma, and are useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemi a, hyperlipidemi a, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR mediated diseases, disorders and conditions.
    Type: Application
    Filed: July 25, 2001
    Publication date: April 11, 2002
    Inventors: John J. Acton, Regina Marie Black, Anthony Brian Jones, Harold Blair Wood
  • Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
    Patent number: 5719296
    Abstract: Compounds of the formula ##STR1## are inhibitors of peptide binding to major histocompatibility complex type II proteins and are useful in the treatment and prevention of autoimmune diseases including: rheumatoid arthritis, Type I diabetes, multiple sclerosis, lupus erythematosis, Graves disease and pemphigus. The present invention also provides novel compositions, methods of treatment employing the compounds of the present invention and methods of manufacture of the compounds of structural formula (I).
    Type: Grant
    Filed: October 28, 1996
    Date of Patent: February 17, 1998
    Assignee: Merck & Co., Inc.
    Inventors: John J. Acton, III, Alan D. Adams, Jeffrey D. Hermes, A. Brian Jones, William Hugh Parsons, Peter J. Sinclair
  • Cholesterol lowering compounds
    Patent number: 5506262
    Abstract: Disclosed herein are compounds of structural formula (I) ##STR1## which are useful as cholesterol lowering agents. These compounds are also useful as inhibitors of squalene synthetase, inhibitors of fungal growth, inhibitors of farnesyl-protein transferase and farnesylation of the oncogene protein Ras. These compounds are also useful in the treatment of cancer.
    Type: Grant
    Filed: November 10, 1993
    Date of Patent: April 9, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Robert M. Burk, William H. Parsons, John J. Acton, III, Gregory D. Berger, Tesfaye Biftu, Robert L. Bugianesi, Yuan-Ching P. Chiang, Claude Dufresne, Narindar N. Girotra, Robert W. Marquis, Jr., Chan-Hwa Kuo, Sandra P. Plevyak, Mitree M. Ponpipom, Lori L. Whiting, James D. Bergstrom, Conrad Santini